#China #Shanghai #Mabwell #T Cell Engager #6MW5311

Mabwell's Landmark IND Clearance: Targeting Hematologic Cancer with 6MW5311

In a significant step forward for cancer treatment, Mabwell (688062.SH, 02493.HK), a biopharmaceutical company renowned for its innovations, has secured IND clearance from China’s National Medical Products Administration (NMPA) for its new bispecific antibody, 6MW5311. This groundbreaking therapy is designed to target LILRB4 and CD3 for the treatment of hematologic malignancies, such as acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM).

6MW5311 stands out in the field, being the first drug candidate globally to receive clinical trial approval that specifically targets LILRB4/CD3. It has already received similar clearance from the FDA, marking it as a pioneer in this category. The strict regulatory endorsements underscore the potential of 6MW5311 to markedly enhance treatment options for some of the most aggressive blood cancers.

The development of this bispecific T Cell Engager (TCE) leverages Mabwell’s proprietary TCE technology platform. Its innovative “2+1” asymmetric molecular structure allows it to engage both LILRB4 on the tumor and CD3 on T cells. This key interaction forms an immunological synapse, effectively bridging tumor cells and T cells so that T cells can be activated to destroy the tumors. An intriguing feature of 6MW5311 is its unique steric hindrance design, which minimizes CD3 binding in the absence of tumor cells. This ability to activate T cells specifically in the presence of tumor cells significantly enhances safety profiles while also improving therapeutic efficacy.

In laboratory studies, 6MW5311 has demonstrated potent cytotoxic activity against various tumor cell lines as well as patient-derived samples. Additionally, in vivo pharmacodynamics studies revealed that 6MW5311 not only inhibited tumor growth in both high and low LILRB4-expressing AML models, but it also achieved complete tumor eradication in high-expression scenarios. Safety assessments in cynomolgus monkeys further validated the favorable safety profile of this bispecific antibody, highlighting its potential as a safe and effective treatment strategy.

The makers of 6MW5311 are hopeful, especially given the limited treatment options currently available for AML and CMML, which largely rely on chemotherapy and stem cell transplants. Unlike these traditional therapies, no TCE products have been approved for AML and CMML so far, indicating the substantial unmet medical need that 6MW5311 aims to address.

Understanding the Hematologic Malignancies

Hematologic malignancies encompass a diverse range of cancer types that affect blood, bone marrow, and lymph nodes. Acute Myeloid Leukemia (AML), for instance, is a clonal malignancy that originates from myeloid stem cells and is noted for its high mortality rates. Estimates suggest that around 172,400 new AML cases were diagnosed globally in 2022, with projections reaching 221,400 by 2035. In China alone, about 30,800 new AML cases were recorded in 2022, signifying a critical area of focus for oncological research and development.

Chronic Myelomonocytic Leukemia (CMML), on the other hand, combines features of myelodysplastic syndromes and myeloproliferative neoplasms. Patients often face an increased risk of transformation to AML, while current therapeutic solutions remain limited for this rare disease.

Multiple Myeloma (MM) is characterized by the uncontrolled proliferation of plasma cells in the bone marrow leading to significant complications. With MM accounting for about 1-2% of all cancers, the need for innovative therapies continues to grow amid shifting patient demographics and increasing incidence rates.

As medical technology advances, the introduction of innovative therapies like 6MW5311 demonstrates a commitment to improving outcomes for patients battling challenging blood cancers. Mabwell remains steadfast in its mission to provide effective and accessible therapies, continuing to explore the curing potential of their groundbreaking innovations with the vision initiative: Explore Life, Benefit Health.

For more insights regarding Mabwell and its innovative pipeline, visit www.mabwell.com/en.